RESOLUTION AT EXTRA GENERAL MEETING

Aerocrine AB (NASDAQ OMX Stockholm: AERO) held an extra general meeting (“EGM”) on Monday 21 October 2013. The EGM resolved to approve that Aerocrine divests the shares in Aerocrine Europe GmbH (the “Company”) to Morten Gunvad (the “Buyer”).

The Company is a wholly-owned Swiss subsidiary of Aerocrine and conducts limited administrative operations for Aerocrine’s account. The Buyer is, up until October 31, 2013, Vice President Commercial Operations EU & ROW of the Aerocrine group as well as managing director of the Company, meaning that the transfer falls within the scope of Chapter 16 of the Swedish Companies Act (the so-called Leo rules) and thus is subject to approval by the General Meeting of Aerocrine. At the time of the share transfer the Company will basically be an empty shell, and therefore the purchase price will be CHF 20,000 (approx. SEK 140,000), which corresponds to the share capital of the Company. The transfer will be conditional on it being essentially cost neutral to Aerocrine. A sale of the Company therefore is not in itself expected to affect Aerocrine’s financial position. Aerocrine is in the process of forming a new subsidiary in Switzerland to maintain operations and for potential IP purposes.  

Aerocrine is required to disclose the information provided herein pursuant to NASDAQ OMX Stockholm’s rulebook. The information was submitted for publication at 17:35 am on October 21, 2013.